 |
 |
|
News Flash: Autumn/Winter 2006 Drug Delivery launch - DecemberDear Customers, For those of you who need to stay up-to-date with the latest industry developments and assess potential drug delivery partners, the news you've been waiting for has finally arrived. The new Autumn/Winter 2006 issue of the Drug Delivery Report will be available in December. The latest edition of the report features information from Bespak, Phares, NanoDel Technologies, Pfeiffer and others, and discusses the impact of new deals and trends in the drug delivery sector. We hope that you find this issue informative and a valuable resource to aid your deal making activities. Best wishes, |
||
 |
 |
Market News and TrendsDuring October 2006, PharmaDeals® Agreements recorded a total of 18 deals relating to drug delivery, seven more than the number recorded for the previous month. Agreements between start-up companies comprised the larger number of deals, seven in total, while three transactions were between start-up and established companies. Global companies were involved in two deals; academic institutions in four, and financial and government bodies in one each. Unusually, only one of the agreements was a co-development or collaborative deal; however, there were four business acquisitions and four licensing transactions. A range of interest areas were represented, with anti-infective and neurological deals most prolific in number (five and three respectively). Read more... |
||
|
|
||
Featured ArticleFormulation of Poorly Soluble DrugsAccording to recent estimates, nearly 40% of new chemical entities are rejected because of poor biopharmaceutical properties. To counter this problem, pharmaceutical companies are implementing strategies to measure, predict and improve solubility of promising new drug candidates during the preclinical phases of drug development. In this article, Drs Nandita Das and Sudip Das, both based at the College of Pharmacy and Health Sciences at Butler University in Indianopolis, discuss the various technologies for formulating poorly soluble drugs. Read more... |
 |
||
|
|
||
 |
Company ProfilesAdvanced Technology Pharma, Bespak, Flamel Technologies, Pfeiffer |
||
|
|
||
Drug Delivery OpportunitiesDo you know about our drug delivery opportunities database? If you're interested in gaining visibility for your opportunity without giving away too much information, you should register with us now! Information about your opportunity will be posted on the website without detailing your firm's name, thereby protecting your business opportunity. Only those firms which are truly interested in your opportunity will gain access to your valuable product information.For the latest information about our Drug Delivery Opportunities, visit our website or alternatively, request a password to submit your opportunity online. Featured Opportunity Hydrophobic Drug Delivery Systems Administrative Route - Injection Indication - Conversion of hydrophobic drugs into patentable microparticles or nanoparticles Licence code - LO-0406-22 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Autumn / Winter 2006For deal makers actively assessing drug delivery technologies, the current complimentary issue of the Drug Delivery Report is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail enquiries@pharmaventures.com with the words UNSUBSCRIBE DDR as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail enquiries@pharmaventures.com with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@pharmaventures.com